RecruitingNCT07144306
AI-Driven Early Detection of Skin Cancer
Sponsor
Nuvana Healthcare LTD
Enrollment
100 participants
Start Date
Oct 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Eligibility
Min Age: 18 Months
Inclusion Criteria2
- Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
- Ability to provide informed consent.
Exclusion Criteria2
- Inability to provide informed consent.
- Poor-quality images unsuitable for AI analysis.
Interventions
DIAGNOSTIC_TESTSmartphone-based AI skin lesion analysis (NuvanaDx platform).
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07144306